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Abstract: Ankylosing spondylitis is a chronic inﬂ  ammatory condition which preferentially 
affects the axial skeleton, often beginning in the sacroiliac joints. The etiology of the pathologic 
lesions of this condition including enthesitis, erosive articular changes, osteitis, and ﬁ  brous 
ankylosis, as well as changes which occur in the eye, gastrointestinal tract, cardiovascular system, 
and lungs is unknown; however, there is a strong association with HLA-B27, which indicates 
altered immunity. One of the major mediators of the immune response is TNF-α, which func-
tions as a pleiotrophic soluble messenger primarily from macrophages. TNF-α is principally 
involved with activation of both normal and transformed cells, including endothelium, synovio-
cytes, osteoclasts, chondrocytes, and ﬁ  broblasts. The cornerstone of medical management of 
ankylosing spondylitis includes intensive physical therapy and nonsteroidal anti-inﬂ  ammatories 
for symptomatic relief. However, it is becoming increasingly recognized that TNF-α blockade 
has an important role in the reduction of spine and joint inﬂ  ammation. This review discusses 
the data that supports use of etanercept in the treatment of ankylosing spondylitis.
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Introduction
Ankylosing spondylitis is a disease included within the entity of spondyloarthopathies. 
This group also includes reactive arthritis, inﬂ  ammatory-bowel-disease-associated 
arthropathy, psoriatic arthritis, and undifferentiated spondyloarthopathy. Ankylosing 
spondylitis is regarded as the most common subtype. Incidence rates of 0.5–8.2/100,000 
population and prevalence rates of 0.2%–1.2% have been described for ankylosing spon-
dylitis, compared with approximately double these ﬁ  gures for the entire group of spon-
dyloarthopathy (Sieper et al 2006). The salient similar features within this group include: 
inﬂ  ammatory spinal pain; radiological sacroilitis with or without clinical spondylitis; 
peripheral inﬂ  ammatory arthritis, usually of the large joints of the lower extremities in an 
asymmetric, pauci-articular fashion; familial tendency; and negative tests for rheumatoid 
factor as well as the absence of subcutaneous rheumatoid nodules. 
The European Spondyloarthropathy Study Group (ESSG) criteria (Table 1) pro-
posed in 1991 has been used to identify patients with spondyloarthopathy; however, 
in clinical practice these criteria are believed to be inadequate (Amor et al 1994). 
There are no uniformly accepted classiﬁ  cation criteria for distinguishing ankylosing 
spondylitis from the other spondyloarthopathies. The most widely accepted diagnostic 
criteria for ankylosing spondylitis are the Modiﬁ  ed New York Criteria developed in 
1984. These require a patient to have low back pain of at least 3 months’ duration 
improved by exercise and not relieved by rest, limitation of lumbar spine motion in 
sagittal and frontal planes, and/or chest expansion decreased relative to normal values 
for age and sex in addition to unilateral sacroiliitis grade 3–4 or bilateral sacroiliitis 
grade 2–4 in order to be diagnosed with ankylosing spondylitis (Table 2) (Van der Lin 
et al 1984). These criteria are often used to identify patients to enroll in investigational Biologics: Targets & Therapy 2007:1(1) 46
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trials in ankylosing spondylitis. In clinical practice, ESSG 
criteria are inadequate for the diagnosis in individual patients 
as they were designed as classiﬁ  cation criteria, with conse-
quent high speciﬁ  city and lower sensitivity.
The modiﬁ  ed New York Criteria reﬂ  ect that radiologically, 
ankylosing spondylitis manifests earliest in the sacroiliac 
joint. Initially, this may appear as pseudowidening of the joint 
with sclerosis in the lower third joint margins. With more 
advanced disease, erosions occur, followed by bony fusion. 
Although magnetic resonance imaging (MRI) and com-
puted tomography are more sensitive to changes occurring 
within the sacroiliac joints than conventional radiography, 
the modiﬁ  ed New York criteria do not currently encompass 
this principle (Braun et al 1994). Thus, intervention outcomes 
do not address the earliest stages of diseases in most clinical 
studies, since study participants are generally included based 
on conventional radiographic data. 
Recent attention has focused on earlier diagnosis 
of ankylosing spondylitis among patients with chronic 
low back pain. This is important as effective biological 
therapies for early treatment have become available. 
Rudwaleit and colleagues have recently shown that it is 
possible to make a diagnosis of inflammatory back pain 
associated with ankylosing spondylitis when at least two 
of the following features are present: 1) morning stiff-
ness >30 minutes, 2) improvement with exercise, but 
not with rest, 3) awakening during the second half of the 
night because of back pain and alternating buttocks pain 
(Rudwaleit et al 2006). If three of the four parameters are 
seen, then a disease probability of more than 90% can be 
achieved. The addition of unilateral or bilateral Grade 3 
sacroiliitis is diagnostic for ankylosing spondylitis.
Both the modiﬁ  ed New York Criteria and Rudwaleit’s cri-
teria highlight the typical clinical presentation of ankylosing 
spondylitis. The insidious alternating buttocks pain and 
stiffness of the spine can lead to deformity and restriction 
of motion secondary to syndesmophytes and alterations at 
the zygo-apophysial joints. The involvement of the thoracic 
spine commonly causes chest expansion restriction due to 
costovertebral joint fusion. The onset of these symptoms 
typically occurs between ages 15–35 years, and severe 
deformity and disability can result within the ﬁ  rst 10 years 
(Gran and Skomsvoll 1997). It tends to affect more men 
than women. In most clinical studies, the activity of disease 
is generally deﬁ  ned by the Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI), and functional status by 
the Bath Ankylosing Spondylitis Disease Functional Index 
(BASFI), with increased levels indicating more severe 
disease.
The goal of treatment in ankylosing spondylitis is to 
ameliorate this pain and stiffness and preserve function. 
Nonselective nonsteroidal anti-inﬂ  ammatories (NSAIDs), 
cyclooxygenase-2 (COX2) selective inhibitors, and nonphar-
malogic interventions, such as physiotherapy and exercise, 
education, and lifestyle modiﬁ  cation are well recognized as 
the most important initial step in management. Second-line 
therapies, such as sulfasalazine for peripheral arthritis, anti-
TNF therapy for axial disease, and extra-articular disease are 
additional management considerations. 
Pathogenesis of ankylosing 
spondylitis
The exact pathogenesis of ankylosing spondylitis is unknown; 
however, both genetics and environment are thought to play 
a role. A genetic predisposition associated with the human 
leukocyte antigen HLA-B27 class molecule is character-
istic in ankylosing spondylitis, with 90%–95% of patients 
Table 1 The European Spondyloarthropathy Study Group 
(ESSG) criteria
Inﬂ  ammatory or synovitis spinal pain and one or more of the following:
 •  Asymmetric
 •  Predominantly
  lower  limb 
  • Alternate buttock pain
 •  Sacroiliitis
 •  Enthesopathy
  •  Positive family history
 •  Psoriasis
 •  Inﬂ  ammatory bowel disease
 •  Urethritis  or 
    cervicitis or acute diarrhea 
    occurring within 1 month  
  before  arthritis
Table 2 Diagnostic criteria for ankylosing spondylitis
Stage I   Grade II or higher bilateral radiographic sacroiliitis
Stage II  Minor radiographic evidence of spinal involvement in 
  ≤1 spinal segment (≤3 vertebrae which equals <15% of
 the  spine) 
Stage III  Moderate radiographic evidence of spinal involvement 
 in  ≤2 spinal segments (4–12 vertebrae which equals
 15–<50% of the spine)
Stage IV  Radiographic evidence of spinal involvement in >2 spinal 
  segments (13–19 vertebrae which equals 50%–<80% of
 the  spine)
Stage  V Widespread  (≥80%) fusion of the spine (≥20 vertebrae)
Adapted from Braun et al (2002).Biologics: Targets & Therapy 2007:1(1) 47
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of European descent carrying this marker (Reveille 2001). 
Multiple different theories have been proposed in attempt 
to explain the association of the HLA-B27 with ankylosing 
spondylitis. 
The T-cell receptor theory is based on knowledge that 
this receptor recognizes only peptides that are in associa-
tion with class I or class II MHC (Major Histocompatibility 
Complex) molecules. The T-cell response is thus restricted 
by HLA molecules. Despite an extensive search there is a 
lack of evidence for a special pathogenic peptide that binds 
HLA-B27, and most HLA-B27 carriers are free from disease; 
thus the receptor theory has a serious weakness (Ebringer 
and Wilson 2000).
The molecular mimicry theory suggests that disease results 
from antigenic components of micro-organisms which partial-
ly cross-react with or resemble HLA molecules (Ebringer and 
Wilson 2000). Not only has amino-acid sequence homology 
between Kleibsiella pneumoniae and HLA-B27 been demon-
strated, but mean IgA antibody levels against this organism 
is higher in active ankylosing spondylitis patients (Ebringer 
and Wilson 2000). Similarly, it has been demonstrated that 
anti-Sacchromyces cerevisiae IgA antibodies are elevated in 
ankylosing spondylitis (Hoffman et al 2003).
It is possible HLA-B27 could result in impaired bacterial 
elimination. It has been suggested that misfolding during 
intracellular assembly process induces the activation of the 
inﬂ  ammatory response following induction of endoplasmic 
reticulum stress, thus independently of antigen presentation 
(Colbert 2000). The misfolded HLA-B27 has the capacity 
to form covalent heavy-chain homodimers amenable to 
recognition by leukocyte receptors, thus immunomodulating 
both innate and adaptive responses to arthritogenic pathogens 
(Lopez de Castro 2007).
One of the key inﬂ  ammatory mediators of the immune 
response is TNF-α. This cytokine plays a critical role in 
the regulation of inﬂ  ammation and clearly has a role in the 
pathogenesis of ankylosing spondylitis. TNF-α serum levels 
are signiﬁ  cantly higher in ankylosing spondylitis patients 
than in patients with noninﬂ  ammatory back pain (Gratacos 
et al 1994). Elevated levels of TNF-α messenger RNA and 
protein were found in ankylosing spondylitis sacroiliac joint 
biopsy specimens (Braun et al 1995).
TNF-α is a cytokine synthesized and secreted primarily 
by macrophages in response to proinﬂ  ammatory stimuli, such 
as bacterial lipopolysacchride (Ellerin et al 2003). It functions 
to increase inﬂ  ammation, cell inﬁ  ltration by upregulation 
of adhesion molecules, angiogenesis, upregulation of acute 
phase response, and articular cartilage degradation, and, in 
a paracrine manner stimulates other cytokines, such as IL-1, 
which results in bone resorption. This inﬂ  ammatory pathway 
is initiated when TNF is cleaved from the cell surface by a 
speciﬁ  c metalloproteinase and binds to its two receptors, 
TNFR-55 and TNFR-75, found in both soluble forms and on 
somatic cell surfaces. Studies have shown that neutralization 
of TNF by the chimeric monoclonal IgG1 antibody inﬂ  ix-
imab, the recombinant 75 kDa TNF receptor IgG1 fusion 
protein etanercept, and the fully humanized monoclonal 
antibody adalimumab can decrease this cascade of events. 
Several associated extra-articular manifestations are 
not included in the deﬁ  nition of ankylosing spondylitis, but 
are well recognized and have additional management con-
siderations. Eye inﬂ  ammation, especially acute anterior 
uveitis, has a likelihood of 1:4 in ankylosing spondylitis 
(Feltkamp and Ringros 1998). The prognosis of uveitis is 
usually good with topical treatment, but might beneﬁ  t from 
additional immunosuppressive therapy if chronicity devel-
ops (De Keyser et al 2004). A meta-analysis of four pla-
cebo-controlled and three open-label studies showed that 
anterior uveitis occurs less frequently in patients treated 
with TNF-α blocking agents (Braun et al 2005). There 
is some evidence that inﬂ  iximab is more effective than 
etanercept in the treatment of recalcitrant uveitis (Galor 
et al 2006). Subclinical gut inﬂ  ammation is also described 
as having a higher incidence in ankylosing spondylitis 
patients with peripheral arthritis (De Keyser et al 1998). 
Of interest, remission of joint inﬂ  ammation is associated 
with a disappearance of the gut inﬂ  ammation (Mielants 
et al 1995). Furthermore, the prevalence of ischemic 
heart disease, atherosclerosis, peripheral vascular disease, 
congestive heart failure, cerebrovascular disease, type II 
diabetes, hyperlipidemia, and hypertension are also higher 
in patients with ankylosing spondylitis than age-controls 
(Han et al 2006). In addition to traditional management of 
these problems, there is some evidence that TNF-α block-
ade in ankylosing spondylitis patients may modulate the 
inﬂ  ammatory process of athersclerosis and induce a mod-
est, but sustained, increase in serum HDL-C levels, which 
may have a favorable effect in reducing the cardiovascular 
risk in these patients (Spanakis et al 2006). The effect of 
TNF-α on aortitis as well as pulmonary disease, such as 
apical ﬁ  brosis, interstitial lung disease, emphysema, bron-
chietasis and pleural thickening, in ankylosing spondylitis 
patients remains to be seen. In one study, no correlation 
was observed between high-resolution computed tomog-
raphy of the chest abnormalities, pulmonary function test 
variables, and indices of ankylosing spondylitis symptoms Biologics: Targets & Therapy 2007:1(1) 48
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and disease structural severity, possibly suggesting a 
different pathogenesis (Quismorio 2006). Complications 




New guidelines for the treatment of ankylosing spondylitis 
have been recently published by the ASsessment in Ankylos-
ing Spondylitis (ASAS) working group, in collaboration with 
EULAR, based on a systemic review of the literature and 
expert opinion (Zochling et al 2006a, b). It was determined 
that nonpharmalogic interventions, such as physiotherapy 
and exercise, education, and lifestyle modiﬁ  cation should 
be offered to all ankylosing spondylitis patients early and 
throughout the illness course (Dagﬁ  nrud et al 2005). 
Meta-analyses of randomized, controlled trials suggest 
that nonselective nonsteroidal anti-inﬂ  ammatories (NSAIDs) 
and cyclooxygenase-2 (COX2) selective inhibitors are ﬁ  rst-
line therapy for all ankylosing spondylitis patients with pain 
and stiffness. Continuous treatment with NSAIDs is capable 
of slowing down the progression the disease (De Keyser et al 
2004). Safety concerns, such as gastrointestinal erosion, must 
be considered when prescribing NSAIDs.
For those refractory or intolerant to NSAIDs, the disease-
modifying antirheumatic drugs (DMARDs) have been used 
as a second-line approach. Sulfasalazine has demonstrated 
some beneﬁ  t in relieving peripheral joint manifestations, 
reducing erythrocyte sedimentation rate (ESR) and easing 
morning stiffness, but has no evidence of beneﬁ  t in physical 
function, spinal mobility, pain, enthesitis, and patient-rated 
and physician-rated global assessment (Dougados et al 1995; 
Clegg et al 1999; Chen and Liu 2005). High-quality random-
ized, controlled trials of long duration and with large sample 
size are needed to clarify the effects of methotrexate (Chen 
et al 2006). Currently there is not enough evidence to support 
any beneﬁ  t of methotrexate, cyclosporine, or azathioprine in 
the treatment of ankylosing spondylitis. 
The ASAS working group, in collaboration with European 
League Against Rheumatism (EULAR), also determined 
that robust evidence is available for the cost-effectiveness of 
TNF-α inhibitors. The consensus of the expert panel was that 
anti-TNF-α treatment should be offered to all patients with 
high disease activity. Three anti-TNF-α agents (etanercept, 
inﬂ  iximab, and adalimumab) have been studied for treatment 
of ankylosing spondylitis and are FDA approved. 
Although there is some evidence to support the use of 
anakinra, thalidomide, and pamidronate in the treatment 
of ankylosing spondylitis, use of these agents was not 
endorsed by the expert panel (Maksymowych et al 1998; 
Huang et al 2002; Tan et al 2004). Of interest, thalidomide 
inhibits TNF-α by amplifying the degradation of messenger 
RNA and decreases the expression of certain cytokines.
Although there is no single accepted clinical parameter 
available for assessing spinal deformity and facilitating 
decision-making about surgical treatment of spinal defor-
mity, spinal stenosis, and hip disease, surgery may become 
necessary for ankylosing spondylitis patients with refractory 
pain and disability. Surgical intervention is indicated when 
fracture and dislocation result in neurological involvement 
(Fox et al 1993). Even in the absence of neurological signs, 
if atlanto-axial and atlanto-occipital subluxation progresses 
substantially and the patient has severe pain and instability, 
surgical fusion may be necessary (Ramos-Remus et al 1997). 
Total hip arthroplasty is likely beneﬁ  cial in patients with 
refractory pain or disability.
Etanercept
Etanercept is a fusion protein consisting of the extracellular 
portion of a human TNFR-75 fused to the Fc region of human 
IgG subclass I molecule. It is administered by subcutaneous 
self-injection, usually in a 50 mg once-a-week, or 25 mg 
twice-a-week dosing regimen. It binds to TNF-α preventing 
it from associating with the cell surface TNF-α receptor, and 
mimics the normal physiologic pathway of down-regulating 
TNF-α. 
Clinical trial data show that TNF-α inhibitors are well 
tolerated by ankylosing spondylitis patients in the short-
term. Injection site reactions of mild to moderate severity 
occur, and are managed with antihistamines, injection of 
hydrocortisone or, less commonly, cessation of therapy 
(Nash and Florin 2005). TNF inhibitors should be avoided in 
patients with advanced heart failure, since large phase II and 
III trials with TNF-α antagonists have shown trends towards 
a worse prognosis in this population. TNF-α inhibitors are 
also associated with the formation of auto-antibodies, though 
these auto-antibodies are rarely associated with any speciﬁ  c 
clinical syndrome. Rare cases of aplastic anemia, pancytope-
nia, vasculitis, and demyelination have also been described 
with anti-TNF therapy (Desai and Furst 2006). 
No head-to-head trials have been done between the 
TNF-α inhibitors; thus although all have been proven to 
have favorable treatment results, none have proven to be 
superior to each other. Because most available data are on 
the ﬁ  rst FDA-approved TNF-inhibitor etanercept for treat-
ment in ankylosing spondylitis, this paper will focus on this Biologics: Targets & Therapy 2007:1(1) 49
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medication. It is recognized that this focus has the limitation 
of collectively including only approximately 400 patients 
with limited study duration and methodology.
Clinical studies have proven the efﬁ  cacy of etanercept 
for ankylosing spondylitis. Marzo-Ortega and colleagues 
preformed the ﬁ  rst descriptive longitudinal clinical study on 
the use of subcutaneous etanercept in 10 spondyloarthropathy 
patients with active inﬂ  ammatory spinal and peripheral joint 
involvement in 2001. Statistically signiﬁ  cant improvement 
was seen in all clinical and functional variables. MRI data 
revealed regression or resolution of enthesal lesions, and 
absence of new lesions in 9 of the patients analyzed (Marzo-
Ortega et al 2001). This study was limited by both the small 
number of patients as well as by the short 24-week duration 
of follow-up. This makes it difﬁ  cult to make conclusions 
on long-term efﬁ  cacy and safety. 
Additional support for the use of etanercept in ankylosing 
spondylitis was provided by Gorman and colleagues. Forty 
patients with active ankylosing spondylitis were enrolled into 
a randomized, double-blind, placebo-controlled trial with 
an option of 6-month of open-label extension. The primary 
outcome measure was composite treatment response of 20% 
or greater improvement in at least three of the following: 
morning stiffness, nocturnal pain, BASFI, patient global 
assessment of disease activity, and score for joint swelling. 
At the end of a 4-month period 75% of the etanercept-treated 
patients had improved clinically, compared with 25% of the 
patients in the placebo group. Improvement was sustained 
over time (Gorman et al 2002). These marked changes that 
resulted from etanercept therapy were mostly subjective. The 
failure of improvement in the modiﬁ  ed Schober’s Index, 
the occiput-to-wall measurement, the Fatigue Severity Scale, 
and the counts and scores for tenderness in peripheral joints 
with etanercept therapy are important ﬁ  ndings in this study. 
The rapid onset of therapeutic relief was demonstrated by 
Calin and co-workers (Calin et al 2004). The efﬁ  cacy of etan-
ercept compared with placebo in 84 patients at 14 European 
centers over 12 weeks. The primary efﬁ  cacy endpoint was 
an improvement of at least 20% in patient-reported symp-
toms, based on the multicomponent ASAS response criteria 
(ASAS 20). ASAS is a composite measure of improvement 
in ankylosing spondylitis symptoms that include total back 
pain, patient assessment of disease activity, inﬂ  ammation, 
and physical function. Signiﬁ  cantly more etanercept patients 
than placebo patients responded at the ASAS 20 level as early 
as week 2, and sustained differences were evident up to week 
12. Etanercept was well tolerated. Most adverse events were 
mild to moderate; the only between-group difference was 
injection site reactions, which occurred signiﬁ  cantly more 
often in etanercept. However, this study was of short duration 
and thus long-term safety data cannot be inferred.
Etanercept has also been evaluated in a larger 24-week 
randomized, multicenter, double-blind, placebo-controlled 
study with open-label extension (Davis et al 2003). In 
the initial study 277 ankylosing spondylitis patients were 
randomized to receive etanercept or placebo. The primary 
endpoints were the proportions of patients achieving ASAS 
20 criteria at 12 and 24 weeks. By week 12, 60% of the 
patients in the etanercept group were ASAS 20 responders 
compared with 27% of placebo-treated patients. Similar 
ASAS 20 responder rates were observed at the end of the 
24-week assessment, 58% of etanercept patient compared 
with 23% of the placebo group. The etanercept group also 
had a signiﬁ  cantly greater improvement in spinal mobility 
measures. No unexpected adverse effects or infections were 
observed.
Davis and colleagues performed a follow-up study 
to monitor extended efﬁ  cacy and safety in patients with 
ankylosing spondylitis, and to determine efﬁ  cacy in patients 
previously receiving placebo (Davis et al 2005). This study 
conﬁ  rmed that ASAS responses to etanercept treatment 
were sustained for almost 2 years, with 74% of patients 
achieving an ASAS 20 response after 96 weeks of etanercept 
treatment.
Similar long-term efﬁ  cacy results were demonstrated by 
Brandt and co-workers in a double-blind, placebo-controlled 
trial. In this 54-week open observational study, 26 ankylosing 
spondylitis patients received etanercept after several months of 
discontinuation following a 6-month randomized control trial 
with the same agent. All patients who developed high disease 
activity after cessation of etanercept, deﬁ  ned as a BASDAI 
and pain greater than or equal to four on a numerical rating 
scale, entered the study. Standard assessment tools, such as 
BASFI, were used. An intention-to-treat (ITT) and a completer 
analysis were performed. The results were compared with 
the baseline values of the open study. Out of the initial 30 
patients, 26 (87%) were eligible for the open extension study 
after a mean of about 27 weeks. At week 54, 88% were still on 
treatment with etanercept. The ITT analysis showed that 58% 
(95% conﬁ  dence interval 39%–74%) of the patients achieved 
a 50% improvement of BASDAI at week 54. According to the 
ASAS working group criteria, 31% were in partial remission 
at week 54. Function, metrology, and quality of life improved 
signiﬁ  cantly. Only one patient had a serious adverse event (new 
onset of biopsy proven Crohn’s) that resulted in discontinua-
tion (Brandt et al 2005). Biologics: Targets & Therapy 2007:1(1) 50
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TNF-α is an essential cytokine in the innate immune 
response and defective host defense mechanisms may play a 
role in the pathogenesis of ankylosing spondylitis; thus there 
has been a concern of severe infectious complications with 
TNF-α blockade in spondyloarthropathy. The extent of the 
infectious complications with TNF-α inhibition can range 
from localized to disseminated. It appears that not only is 
the incidence of certain infections increased with anti-TNF-α 
therapy, but the ability to contain these infections is also 
impaired (Ellerin et al 2003). The extent of the infections 
ranges from localized to disseminated. Serious infections 
have included septic arthritis, infected prostheses, and a 
variety of opportunist infections (Giles and Bathon 2004). 
Reactivation of latent tuberculosis early after commence-
ment of anti- TNF-α therapy and dissemination in a miliary 
fashion is a particular concern, and patients commencing 
anti-TNF-α therapy should have a screening chest X-ray 
and Mantoux test (Nash and Florin 2005). Isoniazid therapy 
for 9 months is indicated if anti-TNF-α therapy is deemed 
necessary and the Mantoux result is signiﬁ  cantly positive 
(Ormerod 2004). Additionally, preliminary data suggest 
that anti-TNF-α therapy may be safe in chronic hepatitis C. 
However, TNF-α antagonists have resulted in re-activation 
of chronic hepatitis B if not given concurrently with antiviral 
therapy (Desai and Furst 2006).
TNF-α also has a role in immune regulation. Anti-TNF 
therapy use in patients with other inﬂ  ammatory arthritides has 
suggested increases in demyelination and serious infection 
(Mohan et al 2001; Salliot et al 2007). These inﬂ  ammatory 
conditions are associated with an increased risk of lymphoma. 
It is unclear whether this risk exists in ankylosing spondy-
litis (Askling et al 2006). Since variable rates of increased 
lymphoma risk have been described with anti-TNF therapy 
compared with the general population, long-term controlled 
and adequately powered follow-up studies are required to 
settle this issue. Solid tumors do not appear to be increased 
with anti-TNF therapy (Desai and Furst 2006). However, 
the existing clinical trial data are underpowered to assess 
long-term, serious adverse outcomes in ankylosing spon-
dylitis patients. Data are also limited for use of anti-TNF 
therapy in pregnancy or lactation. 
Conclusion 
The current management approach to ankylosing spondylitis 
requires a combination of nonpharmacologic and pharma-
cologic treatment modalities. Appropriate and timely use of 
TNF-α antagonists is an additional option for patients with 
active ankylosing spondylitis who are inadequately controlled 
with conventional treatment. TNF-α inhibitor therapies have 
demonstrated rapid and consistent effectiveness in reducing 
the axial and peripheral symptoms of ankylosing spondylitis, 
and improving patient function and quality of life. There are 
data showing that TNF-α inhibition may also have a positive 
effect on anterior uveitis and cardiovascular disease seen in 
ankylosing spondylitis patients. Randomized, controlled tri-
als are needed to further investigate anti-TNF therapy effect 
on other extra-articular aspects of ankylosing spondylitis. 
Additional studies are also needed to establish long-term 
safety, and determine whether these agents can halt disease 
progression in patients. Comparison studies between the three 
FDA-approved TNF inhibitors in ankylosing spondylitis 
patients will be helpful to determine if superiority exists, 
or if switching between biologics is of therapeutic value. 
Incorporation of pre-radiographic changes and MRI data 
will also be an important area of focus in the future for both 
deﬁ  ning interventional strategies and deﬁ  ning the entity of 
ankylosing spondylitis.
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